Clinical trials: Obesity & Overweight
Type 2 Diabetes
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in…
- Trial name
- NCT05134662
- Testing
- ALT-801
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Altimmune, Inc.
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Monogenic Obesity
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity.
- Trial name
- NCT07220772
- Testing
- Mibavademab
- Where
- 3 sites in Germany, Turkey (Türkiye)
- Volunteers
- 4 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Healthy Participants
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
- Trial name
- NCT07911514
- Testing
- AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight, Obesity
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese.
- Trial name
- NCT06606106
- Testing
- LY3537031
- Where
- 5 sites in United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on: weight loss and waist circumference, blood pressure, cholesterol, glucose other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α…
- Trial name
- NCT00134199
- Testing
- CP-945,598, sibutramine
- Where
- 15 sites in United States
- Volunteers
- 282 people
- Sponsor
- Pfizer
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage.
- Trial name
- NCT07097987
- Testing
- WM formula Group, Control group
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Obesity, Overweight
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine.
- Trial name
- NCT06719011
- Testing
- NNC0174-1213 A, Cagrilintide B
- Where
- 2 sites in United States
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Obesity
Prospective Multicenter Study With the Endomina® Triangulation Platform
This registry is designed to further assess on a larger scale safety and efficacy of the endomina® device and tissue apposition accessories (TAPES) when used in the frame of "real life" routine clinical practice
- Trial name
- PRETTi (NCT05677464)
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Endo Tools Therapeutics S.A.
Overweight and Obesity, Healthy
Reason to Season; Flavors to Increase Vascular Health
Scientific evidence is growing on the health benefits of herbs/spices. The study is interested in understanding how various herb and spice blends influence the function of blood vessels.
- Trial name
- SPC (NCT04339114)
- Testing
- Breakfast: control meal, Breakfast: Cinnamon meal, Breakfast: Italian herbs meal
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity
The USGI Medical ESSENTIAL Study for Weight Loss
This is a multicenter, randomized, evaluator and subject blinded, parallel-group, controlled study intended to evaluate the safety and efficacy of treating obese patients with the placement of g-Cath EZ suture anchors followed by…
- Trial name
- NCT01958385
- Testing
- placement of g-Cath EZ suture anchors, Diet and Exercise
- Where
- 11 sites in United States
- Volunteers
- 377 people
- Sponsor
- USGI Medical
Over Weight, Obesity
Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers
The study will assess the safety and performance of an intragastric auto-inflating and degradable balloon
- Trial name
- NCT01753609
- Testing
- Tulip capsule
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tulip Medical Ltd.
Healthy Participants Study, Overweight and Obese Adults
A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults.
- Conditions
- Healthy Participants Study, Overweight and Obese Adults, First in Man Study to Evaluate Initial Safety
- Trial name
- NCT07721597
- Testing
- ZP6590, solution for injection
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Obesity
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose.
- Trial name
- NCT00563368
- Testing
- VI-0521, topiramate, phentermine
- Where
- 2 sites in United States
- Volunteers
- 756 people
- Sponsor
- VIVUS LLC
Overweight, Obesity
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity.
- Trial name
- NCT04012255
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Obesity Associated With Defects in Leptin-melanocortin Pathway
Open-Label Extension Study of Setmelanotide
This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous…
- Trial name
- NCT06596135
- Testing
- Setmelanotide
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Overweight , Obesity
Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity
This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population.
- Trial name
- NCT07331974
- Testing
- AKM Lab-01
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Obesity
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671.
- Trial name
- NCT07815678
- Testing
- ACCG-2671
- Where
- 6 sites in United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.